American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The High Mobility Group A1 chromatin regulator drives immune evasion during MPN progression by repressing genes involved in antigen presentation and immune attack
    Meeting Abstract

    Kim, J.; Kim, J. H.; Cope, L.; Li, L.; Rampal, R.; Koche, R.; Williams, D. M.; Spivak, J. L.; Moliterno, A. R.; Resar, L.
    Blood (2021)

    Fulltext@MSK | Save
  • Dose modification dynamics of ponatinib in patients with chronic- phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
    Meeting Abstract

    Jabbour, E.; Deininger, M.; Abruzzese, E.; Apperley, J. F.; Cortes, J. E.; Chuah, C.; DeAngelo, D.; DiPersio, J. F.; Hochhaus, A.; Lipton, J. H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Frontline brentuximab vedotin plus cyclophosphamide, doxorubicin and prednisone in patients with peripheral T-cell lymphoma with less than 10% CD30 expression (SGN35-032, trial in progress)
    Meeting Abstract

    Jagadeesh, D.; Knowles, S.; Horwitz, S. M.
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy of PBCAR0191, an allogeneic `off-the-shelf' CD19-directed CAR-T for patients with relapsed/refractory (R/R) CD19+ B-ALL
    Meeting Abstract

    Jain, N.; Kantarjian, H.; Solomon, S. R.; He, F.; Sauter, C. S.; Heery, C. R.; List, A. F.; Johnson, M. C.; Lou, Y.; Vainorius, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Efficient targeting of CD38 in mature T-cell neoplasms with daratumumab and allogeneic NK cells
    Meeting Abstract

    Johnson, W. T.; Isabelle, C.; Vogel, A. N.; Brammer, J. E.; Boles, A. E.; McConnell, K.; Berge, R.; Nisenfeld, L.; Uppal, G.; Gong, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • TP53 mutations identify high-risk peripheral T-cell lymphoma patients treated with CHOP-based chemotherapy
    Meeting Abstract

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Maccaro, C.; Galasso, N.; Sauter, C. S.; Neuman, R.; Khan, N.; Moskowitz, A. J.; Dogan, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Ghataorhe, P.; McKeown, A.; He, W.; Ling, T.; Jewell, R. C.; Brunner, J.; Byrne, J.; Eliason, L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world experience
    Meeting Abstract

    Hultcrantz, M.; Orozco, J.; Peterson, T. J.; Derkach, A.; Hassoun, H.; Korde, N.; Lu, S. X.; Mailankody, S.; Patel, D.; Shah, U. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase II study of ruxolitinib pre-, during- and post-hematopoietic celltransplantation for patients with primary or secondary myelofibrosis
    Meeting Abstract

    Hobbs, G.; Kim, H. T.; Bottoms, A. J. S.; Byrne, M. T.; Schroeder, M. A.; Tamari, R.; Wall, S. A.; Defilipp, Z.; El-Jawahri, A.; McAfee, S.; more...
    Blood (2021)

    Fulltext@MSK | Save